Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy

Eur J Pharm Biopharm. 2022 Aug:177:260-272. doi: 10.1016/j.ejpb.2022.07.006. Epub 2022 Jul 18.

Abstract

Chemotherapeutic agents can trigger the immune response via inducing immunogenic cell death (ICD), but the weak ICD effect induced by chemotherapy alone limits its lasting antitumor immunotherapy effect. A Cro polymerized prodrug carriers (POEG-b-PCro) with immunostimulatory by ICD induction was developed and co-delivered DOX to generate synergistic ICD induction for chemo-immunotherapy on breast cancer. DOX/POEG-b-PCro micelles displayed prolonged circulation in blood, efficient accumulation in tumors, internalization and then co-released DOX&Cro in tumor cells. Moreover, the DOX/POEG-b-PCro micelles synergistically triggered ICD induction by releasing the nuclear high mobility group box 1 (HMGB1) and down-regulation of c-Met level for generating chemo-immune anti-tumor actions. Importantly, the DOX/POEG-b-PCro micelles synergistically enhanced the tumor cytotoxic T lymphocytes infiltration, concomitant decreasing the immunosuppressive regulatory T (Treg) cells, accompanied with the increased cytokines secretion of IFN-γ and TNF-α, consequently displaying an improved anti-tumor activity in 4 T1 breast cancer mice. Overall, POEG-b-PCro prodrug micelles co-delivered DOX could be served as a promising nano drug delivery system for synergistic ICD induction on breast cancer chemo-immunotherapy.

Keywords: Breast cancer; Chemo-immunotherapy; DOX; ICD; POEG-b-PCro prodrug.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Crizotinib* / pharmacology
  • Doxorubicin* / pharmacology
  • Immunogenic Cell Death
  • Immunotherapy
  • Mice
  • Mice, Inbred BALB C
  • Micelles*
  • Neoplasms*
  • Prodrugs* / pharmacology

Substances

  • Antineoplastic Agents
  • Micelles
  • Prodrugs
  • Crizotinib
  • Doxorubicin